| Bioactivity | Nefopam hydrochloride (Fenazoxine hydrochloride) is a centrally-acting but non-opioid analgesic drug, for the relief of moderate to severe pain. Nefopam hydrochloride targets β-catenin protein level in mesenchymal cells in-vitro and in-vivo[1][2]. |
| Invitro | Nefopam hydrochloride (Fenazoxine hydrochloride) is a non-opioid, non-steroidal, centrally acting analgesic drug that is derivative of the non-sedative benzoxazocine[1].Constitutively elevated β-catenin leads to a delayed and fibrous fracture repair process, and Nefopam inhibits β-catenin mediated signaling during skin wound repair3]. |
| Name | Nefopam hydrochloride |
| CAS | 23327-57-3 |
| Formula | C17H20ClNO |
| Molar Mass | 289.80 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
| Reference | [1]. Kim KH, et al. Rediscovery of nefopam for the treatment of neuropathic pain. Korean J Pain. 2014 Apr;27(2):103-11. [2]. Baht GS, et al. Pharmacologically targeting beta-catenin for NF1 associated deficiencies in fracture repair. Bone. 2017 May;98:31-36. [3]. Poon R, et al. A high throughput screen identifies Nefopam as targeting cell proliferation in β-catenin driven neoplastic and reactive fibroproliferative disorders. PLoS One. 2012;7(5):e37940. |
Nefopam hydrochloride
CAS: 23327-57-3 F: C17H20ClNO W: 289.80
Nefopam hydrochloride (Fenazoxine hydrochloride) is a centrally-acting but non-opioid analgesic drug, for the relief of
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.